CSI Market
Sign In | Register

Invivo Therapeutics Holdings (NVIV) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access NVIV Annual Cash Flow →
Reviewing cash flow data across recent quarters allows users to assess how Invivo Therapeutics Holdings adapts its cash strategy across cycles.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2023)
9 Months 		(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income-6.97
Depreciation & amortization0.03
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Sale of Assets and Asset Impairment Charges0.12
Share-based Compensation0.14
Income (Loss) from Equity Method Investments0.00
Paid-in-Kind Interest0.00
Gain Loss On Derivative Instruments Net Pretax-
Noncash Interest Expense Income Net-
Pension Expense Reversal Of Expense Noncash-
Operating Lease Right Of Use Asset Amortization-
Increase Decrease In Prepaid Expense And Other Current Assets-0.53
Gain Loss On Lease Assignment-0.11
Operating Lease Right Of Use Asset Amortization Expense0.27
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Insurance Settlements Receivable0.00
Increase (Decrease) in Accounts Payable-0.49
Increase (Decrease) in Accrued Liabilities-0.97
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expenses, Other0.83
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.26
Discontinued operations0.00
Net Cash flow from Operating Activities-7.94
Investing Activities
Capital Expenditures-0.03
Sale of Capital Items0.10
Proceeds from Sale of Available-for-sale Securities0.00
Payments to Acquire Available-for-sale Securities0.00
Real Estate Investments0.00
Noncash Disposals Of Property And Equipment-
Noncash Or Part Noncash Divestiture Amount Of Consideration Received-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.07
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-16.50
Proceeds From Issuance Of Common Stock And Warrants Net-
Proceeds From Issuance Of Common Stock And Warrants-
Stock Issued During Period Value Employee Stock Purchase Plan-
Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents16.50
Fair Value Of Warrants Issued In Connection With Underwriting Agreement-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Restricted Cash And Cash Equivalents-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-7.87
Total Cash Flow-7.87
4 historic quarters locked

Sign in to unlock the full Invivo Therapeutics Holdings cash flow history.

Sign In Create Free Account

About Invivo Therapeutics Holdings Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001558370-23-018294

Figures are derived from filed reports and may be restated. Historical data is subject to revision.